3ddp: Difference between revisions

Revision as of 11:52, 23 July 2008

This article has been automatically seeded. Changes to this page should pertain to the PDB entry only and not to the protein or biomolecule in general.

File:3ddp.jpg

Template:STRUCTURE 3ddp

Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor CR8Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor CR8

Publication Abstract from PubMed

Among the ten pharmacological inhibitors of cyclin-dependent kinases (CDKs) currently in clinical trials, the purine roscovitine (CYC202, Seliciclib) is undergoing phase 2 trials against non-small-cell lung and nasopharyngeal cancers. An extensive medicinal chemistry study, designed to generate more potent analogues of roscovitine, led to the identification of an optimal substitution at the N6 position (compound CR8). An extensive selectivity study (108 kinases) highlights the exquisite selectivity of CR8 for CDK1/2/3/5/7/9. CR8 was 2- to 4-fold more potent than (R)-roscovitine at inhibiting these kinases. Cocrystal structures of (R)-CR8 and (R)-roscovitine with pCDK2/cyclin A showed that both inhibitors adopt essentially identical positions. The cellular effects of CR8 and (R)-roscovitine were investigated in human neuroblastoma SH-SY5Y cells. CR8 inhibited the phosphorylation of CDK1 and 9 substrates, with a 25-50 times higher potency compared to (R)-roscovitine. CR8 was consistently more potent than (R)-roscovitine at inducing apoptotic cell death parameters: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)- 2H-tetrazolium reduction (40-fold), lactate dehydrogenase release (35-fold), caspases activation (68-fold) and poly-(ADP-ribose)polymerase cleavage (50-fold). This improved cell death-inducing activity of CR8 over (R)-roscovitine was observed in 25 different cell lines. Altogether these results show that second-generation analogues of (R)-roscovitine can be designed with improved antitumor potential.

CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases., Bettayeb K, Oumata N, Echalier A, Ferandin Y, Endicott JA, Galons H, Meijer L, Oncogene. 2008 Oct 2;27(44):5797-807. Epub 2008 Jun 23. PMID:18574471

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

About this StructureAbout this Structure

3DDP is a Protein complex structure of sequences from Bos taurus and Homo sapiens. Full crystallographic information is available from OCA.

ReferenceReference

CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases., Bettayeb K, Oumata N, Echalier A, Ferandin Y, Endicott JA, Galons H, Meijer L, Oncogene. 2008 Jun 23;. PMID:18574471

Page seeded by OCA on Wed Jul 23 11:52:10 2008

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 1: / Line 1: @@
-'''Unreleased structure'''
+{{Seed}}
+[[Image:3ddp.jpg|left|200px]]
-The entry 3ddp is ON HOLD
+<!--
+The line below this paragraph, containing "STRUCTURE_3ddp", creates the "Structure Box" on the page.
+You may change the PDB parameter (which sets the PDB file loaded into the applet)
+or the SCENE parameter (which sets the initial scene displayed when the page is loaded),
+or leave the SCENE parameter empty for the default display.
+-->
+{{STRUCTURE_3ddp|  PDB=3ddp  |  SCENE=  }}
-Authors: Echalier, A., Endicott, J.A.
+===Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor CR8===
-Description: Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor CR8
-''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri Jul 11 13:06:38 2008''
+<!--
+The line below this paragraph, {{ABSTRACT_PUBMED_18574471}}, adds the Publication Abstract to the page
+(as it appears on PubMed at http://www.pubmed.gov), where 18574471 is the PubMed ID number.
+-->
+{{ABSTRACT_PUBMED_18574471}}
+==About this Structure==
+DDP is a [[Protein complex]] structure of sequences from [http://en.wikipedia.org/wiki/Bos_taurus Bos taurus] and [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3DDP OCA].
+==Reference==
+CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases., Bettayeb K, Oumata N, Echalier A, Ferandin Y, Endicott JA, Galons H, Meijer L, Oncogene. 2008 Jun 23;. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/18574471 18574471]
+[[Category: Bos taurus]]
+[[Category: Cyclin-dependent kinase]]
+[[Category: Homo sapiens]]
+[[Category: Protein complex]]
+[[Category: Echalier, A.]]
+[[Category: Endicott, J A.]]
+[[Category: Atp-binding]]
+[[Category: Cell cycle]]
+[[Category: Cell division]]
+[[Category: Cyclin]]
+[[Category: Cytoplasm]]
+[[Category: Mitosis]]
+[[Category: Nucleotide-binding]]
+[[Category: Nucleus]]
+[[Category: Phosphoprotein]]
+[[Category: Phosphorylation]]
+[[Category: Polymorphism]]
+[[Category: Ser/thr protein kinase]]
+[[Category: Serine/threonine-protein kinase]]
+[[Category: Transferase/cell cycle complex]]
+''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Jul 23 11:52:10 2008''